Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.49
+7.2%
$1.87
$1.29
$13.07
$55.98M-0.07907,755 shs696,253 shs
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
$0.23
-0.4%
$0.21
$0.15
$2.63
$14.28M5.616.44 million shs790,082 shs
Immuneering Co. stock logo
IMRX
Immuneering
$1.70
-5.8%
$1.40
$1.00
$3.83
$61.00M-0.221.14 million shs293,113 shs
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
$1.87
+1.1%
$1.39
$0.81
$1.98
$63.27M-0.38165,985 shs29,655 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-2.11%-4.14%-37.95%-50.27%-88.07%
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
-3.77%0.00%+8.75%-19.52%-87.96%
Immuneering Co. stock logo
IMRX
Immuneering
+9.76%+21.62%+24.14%+8.11%+25.00%
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
+5.71%+12.12%+19.35%+60.87%+41.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
2.4512 of 5 stars
3.50.00.00.02.03.31.3
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
0.7315 of 5 stars
0.03.00.00.01.91.70.6
Immuneering Co. stock logo
IMRX
Immuneering
3.8435 of 5 stars
3.35.00.00.03.63.31.3
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
2.6816 of 5 stars
3.55.00.00.02.21.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
3.08
Buy$22.601,416.78% Upside
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
0.00
N/AN/AN/A
Immuneering Co. stock logo
IMRX
Immuneering
2.50
Moderate Buy$15.33804.62% Upside
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
3.00
Buy$7.00274.33% Upside

Current Analyst Ratings Breakdown

Latest ERNA, BMEA, IMRX, and OKYO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
5/7/2025
Immuneering Co. stock logo
IMRX
Immuneering
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.00
5/6/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $18.00
5/6/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
5/6/2025
Immuneering Co. stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
5/5/2025
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/10/2025
Immuneering Co. stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/2/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $3.00
3/31/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
3/24/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$10.00
3/24/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/A$4.74 per shareN/A
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
$535K26.69N/AN/A$0.41 per share0.56
Immuneering Co. stock logo
IMRX
Immuneering
$320K190.61N/AN/A$3.09 per share0.55
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A($0.20) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$117.25M-$3.55N/AN/AN/AN/A-118.90%-93.66%7/30/2025 (Estimated)
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
-$21.67M-$8.31N/AN/A-7,513.88%N/A-117.48%8/11/2025 (Estimated)
Immuneering Co. stock logo
IMRX
Immuneering
-$53.47M-$1.96N/AN/AN/AN/A-79.19%-69.08%8/5/2025 (Estimated)
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
-$16.83MN/A0.00N/AN/AN/AN/AN/AN/A

Latest ERNA, BMEA, IMRX, and OKYO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$0.84-$0.80+$0.04-$0.80N/AN/A
5/5/2025Q1 2025
Immuneering Co. stock logo
IMRX
Immuneering
-$0.41-$0.42-$0.01-$0.42N/AN/A
3/31/2025Q4 2024
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$1.00-$0.81+$0.19-$0.81N/AN/A
3/20/2025Q4 2024
Immuneering Co. stock logo
IMRX
Immuneering
-$0.42-$0.58-$0.16-$0.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/AN/A
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
N/AN/AN/AN/AN/A
Immuneering Co. stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/A
3.39
3.39
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
N/A
0.48
0.48
Immuneering Co. stock logo
IMRX
Immuneering
N/A
7.99
7.99
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
N/A
0.28
N/A

Institutional Ownership

CompanyInstitutional Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
96.72%
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
70.55%
Immuneering Co. stock logo
IMRX
Immuneering
67.65%
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
2.97%

Insider Ownership

CompanyInsider Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
27.57%
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
1.50%
Immuneering Co. stock logo
IMRX
Immuneering
25.00%
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
40.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
5037.57 million26.25 millionOptionable
Eterna Therapeutics Inc. stock logo
ERNA
Eterna Therapeutics
1062.36 million5.17 millionNo Data
Immuneering Co. stock logo
IMRX
Immuneering
6035.99 million23.29 millionNot Optionable
OKYO Pharma Limited stock logo
OKYO
OKYO Pharma
733.84 million20.15 millionNot Optionable

Recent News About These Companies

OKYO Pharma confirms stability of drug candidate
OKYO Pharma seeks FDA Fast Track for eye pain drug

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Biomea Fusion stock logo

Biomea Fusion NASDAQ:BMEA

$1.49 +0.10 (+7.19%)
Closing price 04:00 PM Eastern
Extended Trading
$1.51 +0.02 (+1.34%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Eterna Therapeutics stock logo

Eterna Therapeutics NASDAQ:ERNA

$0.23 0.00 (-0.43%)
Closing price 04:00 PM Eastern
Extended Trading
$0.24 +0.01 (+4.80%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Immuneering stock logo

Immuneering NASDAQ:IMRX

$1.70 -0.11 (-5.83%)
Closing price 04:00 PM Eastern
Extended Trading
$1.70 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$1.87 +0.02 (+1.08%)
Closing price 03:59 PM Eastern
Extended Trading
$1.76 -0.11 (-5.61%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.